Bluejay Diagnostics Inc (BJDX) USD0.0001

Sell:$1.62Buy:$1.65No change

Prices delayed by at least 15 minutes
Sell:$1.62
Buy:$1.65
Change:No change
Prices delayed by at least 15 minutes
Sell:$1.62
Buy:$1.65
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.

Key people

Neil Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
Douglas C. Wurth
Independent Chairman of the Board
Svetlana Dey
Director
Donald R. Chase
Independent Director
Fred S. Zeidman
Independent Director
Click to see more

Key facts

  • EPIC
    BJDX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US0956335097
  • Market cap
    $2.45m
  • Employees
    7
  • Shares in issue
    1.49m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.